This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
03/27/15 - 10:01:02 AM ET (BATS BZX Real-time Price)
Div Yield: --
IMMU Day's Range
IMMU 52 Week Range
IMMU Business Summary
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States.View IMMU key stats
Immunomedics Inc - IMMU - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Immunomedics Inc as a
Sell with a ratings score of D.
Report Snippet: We rate Immunomedics Inc (IMMU) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.